IL97403A0 - 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones,oxazolidinones,and imidazolidinones and pharmaceutical compositions containing them - Google Patents

3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones,oxazolidinones,and imidazolidinones and pharmaceutical compositions containing them

Info

Publication number
IL97403A0
IL97403A0 IL97403A IL9740391A IL97403A0 IL 97403 A0 IL97403 A0 IL 97403A0 IL 97403 A IL97403 A IL 97403A IL 9740391 A IL9740391 A IL 9740391A IL 97403 A0 IL97403 A0 IL 97403A0
Authority
IL
Israel
Prior art keywords
imidazolidinones
oxazolidinones
hydroxyphenylmethylene
tertiarybutyl
derivatives
Prior art date
Application number
IL97403A
Other languages
English (en)
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of IL97403A0 publication Critical patent/IL97403A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/96—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/36—One oxygen atom
    • C07D263/40—One oxygen atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/46—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL97403A 1990-03-27 1991-03-04 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones,oxazolidinones,and imidazolidinones and pharmaceutical compositions containing them IL97403A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49993790A 1990-03-27 1990-03-27
US07/640,711 US5143928A (en) 1990-03-27 1991-01-18 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents

Publications (1)

Publication Number Publication Date
IL97403A0 true IL97403A0 (en) 1992-06-21

Family

ID=27053353

Family Applications (1)

Application Number Title Priority Date Filing Date
IL97403A IL97403A0 (en) 1990-03-27 1991-03-04 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones,oxazolidinones,and imidazolidinones and pharmaceutical compositions containing them

Country Status (20)

Country Link
US (3) US5143928A (xx)
EP (1) EP0449216B1 (xx)
JP (1) JP3028628B2 (xx)
KR (1) KR0156533B1 (xx)
CN (1) CN1055180A (xx)
AT (1) ATE133945T1 (xx)
AU (1) AU640468B2 (xx)
CA (1) CA2039056C (xx)
DE (1) DE69116909T2 (xx)
DK (1) DK0449216T3 (xx)
ES (1) ES2082875T3 (xx)
FI (1) FI103508B (xx)
GR (1) GR3019272T3 (xx)
HK (1) HK1005186A1 (xx)
HU (1) HU911001D0 (xx)
IE (1) IE911006A1 (xx)
IL (1) IL97403A0 (xx)
NO (1) NO302294B1 (xx)
NZ (1) NZ237565A (xx)
PT (1) PT97169B (xx)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270319A (en) * 1991-09-09 1993-12-14 Warner-Lambert Company 5-hydroxy-2-pyrimidinylmethylene derivatives useful as antiinflammatory agents
CZ181493A3 (en) * 1992-09-10 1994-03-16 Lilly Co Eli The use of rhodanine derivative for the preparation of a pharmaceutical composition reducing level of sugar in blood and for treating alzheimer's disease
JPH07501834A (ja) * 1992-10-06 1995-02-23 チバーガイギー　アクチェンゲゼルシャフト 新規チオセミカルバゾンチオン
US6251928B1 (en) * 1994-03-16 2001-06-26 Eli Lilly And Company Treatment of alzheimer's disease employing inhibitors of cathepsin D
US5594015A (en) * 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
JP3871354B2 (ja) * 1994-07-29 2007-01-24 株式会社フジモト・コーポレーション 新規な２−（ｎ−シアノイミノ）チアゾリジン−４−オン誘導体
TW424087B (en) * 1995-04-06 2001-03-01 Janssen Pharmaceutica Nv 1,3-dihydro-1-(phenylalkenyl)-2H-imidazol-2-one derivatives
EP0914122B1 (en) * 1996-07-11 2003-09-24 Warner-Lambert Company LLC Method for treating and preventing neurodegenerative disorders by administering a thiazolidinone
US6218437B1 (en) 1996-09-30 2001-04-17 The Regents Of The University Of California Treatment and prevention of hepatic disorders
EP1006794B1 (en) * 1997-03-12 2007-11-28 Robert W. Esmond A method for treating or preventing alzheimer's disease
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
MY122454A (en) * 1998-06-05 2006-04-29 Upjohn Co Use of oxazolidinones for the preparation of a medicament for transdermal delivery
US6191154B1 (en) 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
US6730700B2 (en) * 1998-12-02 2004-05-04 Renovis, Inc. 3,4,5,-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same
UA66401C2 (en) 1998-12-02 2004-05-17 Sentor Pharmaceuticals Inc 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical composition containing the same
JP2001072592A (ja) 1999-07-01 2001-03-21 Kyowa Hakko Kogyo Co Ltd テロメラーゼ阻害剤
US6444685B1 (en) 2000-07-17 2002-09-03 Wyeth N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists
US6525202B2 (en) 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US6452014B1 (en) 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
US7041650B2 (en) * 2001-07-09 2006-05-09 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivative salts
DE60234057D1 (de) 2001-07-25 2009-11-26 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
MXPA02010430A (es) * 2001-11-27 2003-06-02 Warner Lambert Co Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas.
AU2003298693B2 (en) * 2002-11-22 2010-09-30 Smithkline Beecham Corporation Novel chemical compounds
US7479507B2 (en) * 2003-01-14 2009-01-20 Adam Heller Anti-inflammatory substituted phenols and elastomeric compositions for oral delivery of drugs
JP4570857B2 (ja) * 2003-03-31 2010-10-27 富士フイルム株式会社 感光性組成物及び平版印刷版原版
EP1889198B1 (en) 2005-04-28 2014-11-26 Proteus Digital Health, Inc. Pharma-informatics system
CN100384828C (zh) * 2005-05-08 2008-04-30 山东大学 (z)-5-[[(3,5-二叔丁基)-4-羟基苯基]亚甲基]-2-亚氨基-4-噻唑啉酮甲磺酸盐的制备方法
PE20070083A1 (es) * 2005-06-08 2007-01-27 Smithkline Beecham Corp (5z)-5-(6-quinoxalinilmetilideno)-2-[(2,6-diclorofenil)amino]-1,3-tiazol-4(5h)-ona
WO2008036682A2 (en) 2006-09-18 2008-03-27 Raptor Pharmaceutical Inc. Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
US20100286041A1 (en) * 2007-03-22 2010-11-11 Smithkline Beecham Corporation (5z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl)amino]-1,3-thiazol-4(5h)-one
FR2919608B1 (fr) * 2007-08-01 2012-10-05 Univ Rennes Derives d'imidazolones,procede de preparation et applications biologiques
DK3395372T3 (da) 2009-02-20 2022-04-19 Enhanx Biopharm Inc System til afgivelse af glutathion-baseret medikament
EP2424521A4 (en) 2009-04-29 2015-03-04 Amarin Pharmaceuticals Ie Ltd PHARMACEUTICAL COMPOSITIONS COMPRISING EPA AND CARDIOVASCULAR AGENT AND METHODS OF USE
EP2427178B1 (en) 2009-05-06 2023-01-04 Laboratory Skin Care, Inc. Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
CN102000487B (zh) * 2010-10-19 2012-09-05 上海海事大学 一种捕捉二氧化碳的方法
CN103044352B (zh) * 2011-10-13 2015-04-29 南京大学 一类噻唑啉酮衍生物及其制法
ES2668310T3 (es) 2012-11-05 2018-05-17 Commissariat à l'énergie atomique et aux énergies alternatives Combinación de un agente anticanceroso tal como un inhibidor de la tirosina cinasa y un antagonista STAT5, preferiblemente una tiazolidindiona, para eliminar las células madre de cáncer hematológico in vivo y para prevenir la recidiva de cáncer hematológico

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1601310A (en) * 1978-05-23 1981-10-28 Lilly Industries Ltd Aryl hydantoins
DE3013626C2 (de) * 1980-04-09 1985-06-27 Degussa Ag, 6000 Frankfurt Verfahren zur Herstellung von 5-Arylidenhydantoinen (A)
DE3013647C2 (de) * 1980-04-09 1985-07-11 Degussa Ag, 6000 Frankfurt Verfahren zur Herstellung von 5-Arylidenhydantoinen (B)
DE3023349A1 (de) * 1980-06-21 1982-01-14 Degussa Ag, 6000 Frankfurt Verfahren zur herstellung von 5-arylidenhydantoinen (c)
US4582903A (en) * 1984-08-17 1986-04-15 Stauffer Chemical Company Synthesis of unsaturated hydantoins with an inexpensive catalyst
US4650876A (en) * 1984-08-17 1987-03-17 Stauffer Chemical Company Hydrogenation of substituted, unsaturated hydantoins to substituted, saturated hydantoins
JPH066571B2 (ja) * 1985-05-09 1994-01-26 エーザイ株式会社 ２−ピロリドン誘導体
JPS6229579A (ja) * 1985-07-29 1987-02-07 Kanegafuchi Chem Ind Co Ltd ４−チアゾリノン誘導体
JPS6229570A (ja) * 1985-07-29 1987-02-07 Kanegafuchi Chem Ind Co Ltd ３，５−ジイソプロピルベンジリデン複素環式化合物
PT83152B (pt) * 1985-08-09 1989-03-30 Lilly Co Eli Processo para a preparacao de compostos di-t-butilfenoicos
JP2539504B2 (ja) * 1987-03-11 1996-10-02 鐘淵化学工業株式会社 ヒドロキシスチレン誘導体
US5208250A (en) * 1988-05-25 1993-05-04 Warner-Lambert Company Known and selected novel arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and anti-inflammatory agents
IE62214B1 (en) * 1988-05-25 1995-01-11 Warner Lambert Co Arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and antiinflammatory agents
ATE139531T1 (de) * 1989-04-07 1996-07-15 Lilly Co Eli Arylsubstituierte rhodaninderivate
IL96654A (en) * 1989-12-21 1995-06-29 Lilly Co Eli Sutral derivatives containing hydroxybenzyl and sulfur-converted, and pharmaceutical preparations containing them
US6127184A (en) * 1998-03-07 2000-10-03 Robert A. Levine Calibration of a whole blood sample analyzer

Also Published As

Publication number Publication date
NO911231L (no) 1991-09-30
JP3028628B2 (ja) 2000-04-04
US5290800A (en) 1994-03-01
HU911001D0 (en) 1991-10-28
KR0156533B1 (ko) 1998-11-16
FI103508B1 (fi) 1999-07-15
FI103508B (fi) 1999-07-15
FI911443A0 (fi) 1991-03-25
JPH04221371A (ja) 1992-08-11
EP0449216B1 (en) 1996-02-07
PT97169B (pt) 1998-07-31
NO911231D0 (no) 1991-03-26
NZ237565A (en) 1993-02-25
FI911443A (fi) 1991-09-28
GR3019272T3 (en) 1996-06-30
ES2082875T3 (es) 1996-04-01
DE69116909T2 (de) 1996-06-13
AU7372191A (en) 1991-10-03
CN1055180A (zh) 1991-10-09
US5143928A (en) 1992-09-01
DE69116909D1 (de) 1996-03-21
EP0449216A1 (en) 1991-10-02
CA2039056C (en) 2001-09-18
US5494927A (en) 1996-02-27
AU640468B2 (en) 1993-08-26
NO302294B1 (no) 1998-02-16
HK1005186A1 (en) 1998-12-24
ATE133945T1 (de) 1996-02-15
PT97169A (pt) 1991-12-31
KR910016724A (ko) 1991-11-05
DK0449216T3 (da) 1996-07-01
IE911006A1 (en) 1991-10-09
CA2039056A1 (en) 1991-09-28

Similar Documents

Publication Publication Date Title
IL97403A0 (en) 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones,oxazolidinones,and imidazolidinones and pharmaceutical compositions containing them
ATE119774T1 (de) Imidazopyridinderivate und ihre verwendung.
IL103875A0 (en) Piperazinyl-and piperidinyl-cyclohexanol derivatives and pharmaceutical compositions containing the same
ES2080327T3 (es) Derivados de acido quinolona-carboxilico.
DK0511541T3 (xx)
NO903640D0 (no) Fremgangsmaate for fremstilling av 2-(rs)-substituerte 2,3-dihydro-5-oksy-4,6,7-trimetylbenzofuraner.
ES2093037T3 (es) Derivados de beta-lactama y su preparacion.
FI943386A0 (fi) CNS-aktiivisuuden omaavia tratsodonin alkyylijohdannaisia
GR3004848T3 (xx)
DE69218205D1 (de) 1,2,4-THIADIAZINO[3,4-b]BENZOTHIAZOL-DERIVATE, IHRE HERSTELLUNG UND SIE ENTHALTENDE ARZNEIMITTEL
DK656889A (da) Azabicykliske derivater
DK669388A (da) Azolderivater
ZA912286B (en) 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones,oxazolidinones,and imidazolidinones as antiinflammatory agents